Clinical Trial Update: 5G-EMERALD: Amivantamab in Malignant Brain Tumours [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of amivantamab for malignant brain tumors, including glioblastoma and related gliomas, is currently recruiting in the United Kingdom.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Hemispheric Glioma H3 G34-mutant
• Glioblastoma
• Malignant Glioma

Drugs mentioned

• Amivantamab (amivantamab)

Snippet

Sponsor: Institute of Cancer Research, United Kingdom | Conditions: Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma) | Phase 1 | Status: RECRUITING